Multidisciplinary Therapy in Men with Newly Diagnosed Oligometastatic Prostate Cancer

References

• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.8
   PubMed Web of Science ®Google Scholar
• Parker CC, James ND, Brawley CD, et al.; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled Phase 3 trial. Lancet. 2018;392(10162):2353–2366. doi:10.1016/S0140-6736(18)32486-3
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy MJ, McBride SM, Vargas HA, et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology. 2017;102:164–172. doi:10.1016/j.urology.2016.10.044
   PubMed Web of Science ®Google Scholar
• Reyes DK, Rowe SP, Schaeffer EM, et al. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol. 2020;37:60. doi:10.1007/s12032-020-01385-7
   PubMed Web of Science ®Google Scholar
• Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058–1066. doi:10.1016/j.eururo.2013.11.012
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835–2842. doi:10.1200/JCO.2016.67.4788
   PubMed Web of Science ®Google Scholar
• Cho Y, Chang JS, Rha KH, et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One. 2016;11(1):e0147191. doi:10.1371/journal.pone.0147191
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008–1012. doi:10.1016/S0022-5347(05)64562-4
   Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–838. doi:10.1016/j.juro.2014.09.089
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al.; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi:10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6:650–659. doi:10.1001/jamaoncol.2020.0147
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II Trial. J Clin Oncol. 2018;36(5):446–453. doi:10.1200/JCO.2017.75.4853
   PubMed Web of Science ®Google Scholar
• Foerster R, Zwahlen DR, Buchali A, et al. Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review. Cancers (Basel). 2021;13(4):759. doi:10.3390/cancers13040759
   PubMed Web of Science ®Google Scholar
• Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–1628. doi:10.3109/0284186X.2013.764010
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Usami M, et al.; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115(15):3437–3445. doi:10.1002/cncr.24395
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al.; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi:10.1056/NEJMoa1704174
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al.; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 381;2019:13–24. doi:10.1056/NEJMoa1903307
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, Phase III Study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986. doi:10.1200/JCO.19.00799
   PubMed Web of Science ®Google Scholar
• Hamano I, Hatakeyama S, Narita S, et al. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol. 2019;37(11):2365–2373. doi:10.1007/s00345-019-02664-3
   Web of Science ®Google Scholar
• Yamashita T, Shiota M, Machidori A, et al. Efficacy and safety of 4-weekly docetaxel for castration-resistant prostate cancer. Cancer Invest. 2021;39(3):251–256. doi:10.1080/07357907.2020.1871486
   PubMed Web of Science ®Google Scholar
• Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(24):7448–7454. doi:10.1158/1078-0432.CCR-19-1050
   PubMed Web of Science ®Google Scholar
• NCT03678025. Standard systemic therapy with or without definitive treatment in treating participants with metastatic prostate cancer. Available from: https://ClinicalTrials.gov/show/NCT03678025. Accessed August 2, 2021.
   Google Scholar